The Third Circuit’s recent rejection in Eisai v. Sanofi-Aventis of allegations of anticompetitive exclusive dealing arrangements in the form of a market-share discount program has been described as “another nail in the coffin” of loyalty discount liability. But to what extent did the court’s decision leave the door open to liability in future cases with different (or better) facts? Did it clarify the line between permissible pro-competitive discounting and customer coercion? Our esteemed panelists will discuss (and debate) these and many other questions raised by the decision. Steve Salop will be a panelist on the this topic.
For more information on this event, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...